$IRON
Disc Medicine, Inc.

2024 Q2 Form 10-Q Financial Statement

#000095017024056304 Filed on May 09, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $7.367M $7.758M
YoY Change 40.86% 56.73%
% of Gross Profit
Research & Development $23.49M $23.70M
YoY Change 94.09% 17.46%
% of Gross Profit
Depreciation & Amortization $110.0K $26.00K
YoY Change 450.0% 4.0%
% of Gross Profit
Operating Expenses $30.85M $31.46M
YoY Change 78.05% 25.22%
Operating Profit -$30.85M -$31.46M
YoY Change 78.05% 25.22%
Interest Expense $4.573M $4.519M
YoY Change 224.33% 90.68%
% of Operating Profit
Other Income/Expense, Net $4.560M $4.518M
YoY Change 224.56% 90.87%
Pretax Income -$26.29M -$26.94M
YoY Change 65.12% 18.39%
Income Tax $60.00K $5.000K
% Of Pretax Income
Net Earnings -$26.35M -$26.95M
YoY Change 65.25% 18.3%
Net Earnings / Revenue
Basic Earnings Per Share -$1.03 -$1.09
Diluted Earnings Per Share -$1.03 -$1.09
COMMON SHARES
Basic Shares Outstanding 24.72M 24.68M
Diluted Shares Outstanding 25.65M 24.81M

Balance Sheet

Concept 2024 Q2 2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $500.9M $342.6M
YoY Change 32.67% 44.93%
Cash & Equivalents $280.7M $342.6M
Short-Term Investments $220.3M
Other Short-Term Assets $7.296M $9.333M
YoY Change 77.95% 63.74%
Inventory
Prepaid Expenses $7.296M $9.333M
Receivables
Other Receivables
Total Short-Term Assets $508.2M $351.9M
YoY Change 33.14% 45.35%
LONG-TERM ASSETS
Property, Plant & Equipment $98.00K $211.0K
YoY Change -38.36% 17.22%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $236.0K $235.0K
YoY Change 103.45% 102.59%
Total Long-Term Assets $1.976M $2.234M
YoY Change -19.05% 36.05%
TOTAL ASSETS
Total Short-Term Assets $508.2M $351.9M
Total Long-Term Assets $1.976M $2.234M
Total Assets $510.2M $354.2M
YoY Change 32.81% 45.29%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.749M $5.269M
YoY Change -8.92% -6.61%
Accrued Expenses $4.451M $8.816M
YoY Change 7.3% 119.03%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $20.31M $14.85M
YoY Change 109.75% 48.82%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $1.078M $1.259M
YoY Change -67.33% 39.89%
Total Long-Term Liabilities $1.078M $1.259M
YoY Change -67.33% 39.89%
TOTAL LIABILITIES
Total Short-Term Liabilities $20.31M $14.85M
Total Long-Term Liabilities $1.078M $1.259M
Total Liabilities $21.39M $16.11M
YoY Change 65.09% 47.47%
SHAREHOLDERS EQUITY
Retained Earnings -$241.9M -$215.6M
YoY Change 60.3% 59.7%
Common Stock $3.000K $2.000K
YoY Change 50.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $488.8M $338.1M
YoY Change
Total Liabilities & Shareholders Equity $510.2M $354.2M
YoY Change 32.81% 45.29%

Cashflow Statement

Concept 2024 Q2 2024 Q1
OPERATING ACTIVITIES
Net Income -$26.35M -$26.95M
YoY Change 65.25% 18.3%
Depreciation, Depletion And Amortization $110.0K $26.00K
YoY Change 450.0% 4.0%
Cash From Operating Activities -$15.39M -$33.60M
YoY Change 21.01% -5.26%
INVESTING ACTIVITIES
Capital Expenditures -$3.000K $67.00K
YoY Change -130.0% 131.03%
Acquisitions
YoY Change
Other Investing Activities -$219.8M
YoY Change
Cash From Investing Activities -$219.7M -$67.00K
YoY Change 2197390.0% 131.03%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 173.2M 15.90M
YoY Change 12.57% -79.43%
NET CHANGE
Cash From Operating Activities -15.39M -33.60M
Cash From Investing Activities -219.7M -67.00K
Cash From Financing Activities 173.2M 15.90M
Net Change In Cash -61.95M -17.77M
YoY Change -143.9% -142.49%
FREE CASH FLOW
Cash From Operating Activities -$15.39M -$33.60M
Capital Expenditures -$3.000K $67.00K
Free Cash Flow -$15.39M -$33.67M
YoY Change 20.9% -5.15%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2024Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q1 dei Amendment Flag
AmendmentFlag
false
CY2024Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001816736
CY2024Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q1 iron Rule10 B51 Arr Modified Flag
Rule10B51ArrModifiedFlag
true
CY2024Q1 iron Non Rule10 B51 Arr Modified Flag
NonRule10B51ArrModifiedFlag
true
CY2024Q1 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
true
CY2024Q1 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
true
CY2024Q1 dei Document Type
DocumentType
10-Q
CY2024Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2024Q1 dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
CY2024Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2024Q1 dei Entity File Number
EntityFileNumber
001-39438
CY2024Q1 dei Entity Registrant Name
EntityRegistrantName
Disc Medicine, Inc.
CY2024Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2024Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
85-1612845
CY2024Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
321 Arsenal Street, Suite 101
CY2024Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Watertown
CY2024Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2024Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02472
CY2024Q1 dei City Area Code
CityAreaCode
617
CY2024Q1 dei Local Phone Number
LocalPhoneNumber
674-9274
CY2024Q1 dei Security12b Title
Security12bTitle
Common Stock, $0.0001 Par Value
CY2024Q1 dei Trading Symbol
TradingSymbol
IRON
CY2024Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2024Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2024Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2024Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2024Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2024Q1 dei Entity Shell Company
EntityShellCompany
false
CY2024Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
24721666
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
342615000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
360382000
CY2024Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
9333000
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
5280000
CY2024Q1 us-gaap Assets Current
AssetsCurrent
351948000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
365662000
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
211000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
170000
CY2024Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1788000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1930000
CY2024Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
235000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
234000
CY2024Q1 us-gaap Assets
Assets
354182000
CY2023Q4 us-gaap Assets
Assets
367996000
CY2024Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
5269000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
12629000
CY2024Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8816000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8145000
CY2024Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
767000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
665000
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
14852000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
21439000
CY2024Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1259000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1436000
CY2024Q1 us-gaap Liabilities
Liabilities
16111000
CY2023Q4 us-gaap Liabilities
Liabilities
22875000
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
24695885
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
24695885
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
24360233
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
24360233
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
2000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
2000
CY2024Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
553663000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
533764000
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-215594000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-188645000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
338071000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
345121000
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
354182000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
367996000
CY2024Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
23704000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
20180000
CY2024Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7758000
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4945000
CY2024Q1 us-gaap Operating Expenses
OperatingExpenses
31462000
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
25125000
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-31462000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-25125000
CY2024Q1 us-gaap Interest Income Other
InterestIncomeOther
4519000
CY2023Q1 us-gaap Interest Income Other
InterestIncomeOther
2367000
CY2024Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1000
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0
CY2024Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
4518000
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2367000
CY2024Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-26944000
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-22758000
CY2024Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
5000
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
23000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-26949000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-22781000
CY2024Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-26949000
CY2024Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-26949000
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-22781000
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-22781000
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
24809869
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
24809869
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
18954914
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
18954914
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.09
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.09
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.2
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.2
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
176600000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1067000
CY2023Q1 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
1024000
CY2023Q1 iron Common Stock In Registered Direct Offering Net Of Issuance Costs
CommonStockInRegisteredDirectOfferingNetOfIssuanceCosts
80000
CY2023Q1 iron Stock Issued During Period Value Sale Of Common Stock In Registered Direct Offering
StockIssuedDuringPeriodValueSaleOfCommonStockInRegisteredDirectOffering
34148000
CY2023Q1 iron Pre Funded Warrants In Registered Direct Offering Net Of Issuance Costs
PreFundedWarrantsInRegisteredDirectOfferingNetOfIssuanceCosts
66000
CY2023Q1 iron Stock Issued During Period Value Sale Of Pre Funded Warrants In Registered Direct Offering
StockIssuedDuringPeriodValueSaleOfPreFundedWarrantsInRegisteredDirectOffering
28206000
CY2023Q1 iron Common Stock In At The Market Offerings Net Of Issuance Costs
CommonStockInAtTheMarketOfferingsNetOfIssuanceCosts
408000
CY2023Q1 iron Stock Issued During Period Value Sale Of Common Stock In At The Market Offerings
StockIssuedDuringPeriodValueSaleOfCommonStockInAtTheMarketOfferings
14591000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-22781000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
232855000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
345121000
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
806000
CY2024Q1 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
4058000
CY2024Q1 iron Common Stock In At The Market Offerings Net Of Issuance Costs
CommonStockInAtTheMarketOfferingsNetOfIssuanceCosts
518000
CY2024Q1 iron Stock Issued During Period Value Sale Of Common Stock In At The Market Offerings
StockIssuedDuringPeriodValueSaleOfCommonStockInAtTheMarketOfferings
14790000
CY2024Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
245000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-26949000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
338071000
CY2024Q1 us-gaap Profit Loss
ProfitLoss
-26949000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-22781000
CY2024Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
26000
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
25000
CY2024Q1 us-gaap Share Based Compensation
ShareBasedCompensation
4058000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1024000
CY2024Q1 iron Noncash Lease Expense
NoncashLeaseExpense
142000
CY2023Q1 iron Noncash Lease Expense
NoncashLeaseExpense
84000
CY2024Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
4112000
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
908000
CY2024Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-7360000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-10750000
CY2024Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
671000
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-2084000
CY2024Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-75000
CY2023Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-76000
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-33599000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-35466000
CY2024Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
67000
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
29000
CY2024Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-67000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-29000
CY2024Q1 iron Proceeds From Sale Of Common Stock In Offerings Net Of Issuance Costs Paid
ProceedsFromSaleOfCommonStockInOfferingsNetOfIssuanceCostsPaid
0
CY2023Q1 iron Proceeds From Sale Of Common Stock In Offerings Net Of Issuance Costs Paid
ProceedsFromSaleOfCommonStockInOfferingsNetOfIssuanceCostsPaid
34217000
CY2024Q1 iron Proceeds From Sale Of Pre Funded Warrants In Offerings Net Of Issuance Costs Paid
ProceedsFromSaleOfPreFundedWarrantsInOfferingsNetOfIssuanceCostsPaid
0
CY2023Q1 iron Proceeds From Sale Of Pre Funded Warrants In Offerings Net Of Issuance Costs Paid
ProceedsFromSaleOfPreFundedWarrantsInOfferingsNetOfIssuanceCostsPaid
28262000
CY2024Q1 us-gaap Proceeds From Sale Of Treasury Stock
ProceedsFromSaleOfTreasuryStock
14849000
CY2023Q1 us-gaap Proceeds From Sale Of Treasury Stock
ProceedsFromSaleOfTreasuryStock
14605000
CY2024Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
806000
CY2023Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
222000
CY2024Q1 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
245000
CY2023Q1 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
0
CY2024Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
15900000
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
77306000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-17766000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
41811000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
360616000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
194788000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
342850000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
236599000
CY2024Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0
CY2023Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0
CY2024Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0
CY2023Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
8000
CY2024Q1 iron Receivable For Proceeds From Stock Option Exercises Included In Other Current Assets1
ReceivableForProceedsFromStockOptionExercisesIncludedInOtherCurrentAssets1
0
CY2023Q1 iron Receivable For Proceeds From Stock Option Exercises Included In Other Current Assets1
ReceivableForProceedsFromStockOptionExercisesIncludedInOtherCurrentAssets1
845000
CY2024Q1 iron Deferred Issuance Costs On Sale Of Common Stock And Pre Funded Warrants In Offerings Included In Accounts Payable And Accrued Expenses1
DeferredIssuanceCostsOnSaleOfCommonStockAndPreFundedWarrantsInOfferingsIncludedInAccountsPayableAndAccruedExpenses1
0
CY2023Q1 iron Deferred Issuance Costs On Sale Of Common Stock And Pre Funded Warrants In Offerings Included In Accounts Payable And Accrued Expenses1
DeferredIssuanceCostsOnSaleOfCommonStockAndPreFundedWarrantsInOfferingsIncludedInAccountsPayableAndAccruedExpenses1
222000
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
342600000
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-215600000
CY2024Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of the Company’s condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to accrued research and development expenses; stock-based compensation expense; the fair value determinations for instruments accounted for at fair value including contingent amounts payable to third parties upon the consummation of specified transactions; the fair value of the contingent value right (“CVR”) (see Note 3); the incremental borrowing rate for determining lease liabilities and right-of-use assets and income taxes. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it has concluded to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates as there are changes in circumstances, facts and experience. Changes in estimates are recorded in the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">period in which they become known. Actual results may differ materially from those estimates or assumptions.</span>
CY2024Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentration of Credit Risk and of Significant Suppliers</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits and limits its exposure to cash risk by placing its cash with high credit quality accredited financial institutions. The Company has concluded that it is not subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company relies, and expects to continue to rely, on a small number of vendors to manufacture supplies and to process its product candidates for its development programs. These programs could be adversely affected by a significant interruption in the manufacturing process or supply chain.</span></p>
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
342615000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
360382000
CY2024Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
235000
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
234000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
342850000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
360616000
CY2024Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
271000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
245000
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
211000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
170000
CY2024Q1 iron Accrued Research And Development Expense
AccruedResearchAndDevelopmentExpense
5749000
CY2023Q4 iron Accrued Research And Development Expense
AccruedResearchAndDevelopmentExpense
1986000
CY2024Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2159000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5790000
CY2024Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
709000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
317000
CY2024Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
199000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
52000
CY2024Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8816000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8145000
CY2024Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2024Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q1 iron Common Stock Authorized And Reserved For Future Issuance
CommonStockAuthorizedAndReservedForFutureIssuance
2948273
CY2024Q1 iron Stock Reserved During Period Shares Exercise Of Prefunded Warrants
StockReservedDuringPeriodSharesExerciseOfPrefundedWarrants
204081
CY2024Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4058000
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1024000
CY2024Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
53348000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2459037
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
13.82
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y9M21D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
109078000
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
616871
CY2024Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
64.59
CY2024Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
95467
CY2024Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
8.44
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
30924
CY2024Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
50.32
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
1244
CY2024Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
14.51
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2948273
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
24.23
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y18D
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
114368000
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1329424
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
10.67
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y11M26D
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
69546000
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
5500000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
500000
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0401
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0386
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y10D
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y18D
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.58
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.62
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2024Q1 us-gaap Share Price
SharePrice
64.59
CY2023Q1 us-gaap Share Price
SharePrice
23.1
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
1500000
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
800000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
0
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
1916
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
0
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
958
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
0
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
958
CY2024Q1 us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
0
CY2023Q1 us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
0
CY2024Q1 us-gaap State And Local Income Tax Expense Benefit Continuing Operations
StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
100000
CY2023Q1 us-gaap State And Local Income Tax Expense Benefit Continuing Operations
StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
100000
CY2023Q3 iron Exercise Of Pre Funded Warrants Shares
ExerciseOfPreFundedWarrantsShares
1229224
iron Stock Issued During Period Shares Warrants Exercised
StockIssuedDuringPeriodSharesWarrantsExercised
1229221
CY2024Q1 iron Pre Funded Warrants Outstanding
PreFundedWarrantsOutstanding
204081
CY2024Q1 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
500000
CY2024Q1 iron Short Term Bank Loans And Notespayable Percentage
ShortTermBankLoansAndNotespayablePercentage
0.045

Files In Submission

Name View Source Status
0000950170-24-056304-index-headers.html Edgar Link pending
0000950170-24-056304-index.html Edgar Link pending
0000950170-24-056304.txt Edgar Link pending
0000950170-24-056304-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
iron-20240331.htm Edgar Link pending
iron-20240331.xsd Edgar Link pending
iron-ex31_1.htm Edgar Link pending
iron-ex31_2.htm Edgar Link pending
iron-ex32_1.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
iron-20240331_htm.xml Edgar Link completed
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending